AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
AN2 Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00QYLYBL3
3.55▼ 0.09 (-2.47%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
3.64
Day's Range
3.47 – 3.66
52-Week Range
1.00 – 7.19
Volume
118.0K
Avg Volume
290.2K
Share Statistics
Shares Outstanding
Employees
21
Exchange
XNAS
Listed
2022-03-25
Share count as of August 6, 2026

AN2 Therapeutics, Inc. Common Stock (ANTX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about AN2 Therapeutics, Inc. Common Stock (ANTX)
What is AN2 Therapeutics, Inc. Common Stock's Market Cap?
AN2 Therapeutics, Inc. Common Stock's Market Cap is $134.0M, based on as-reported figures from SEC (XBRL) filings.
What is AN2 Therapeutics, Inc. Common Stock's Enterprise Value?
AN2 Therapeutics, Inc. Common Stock's Enterprise Value is $89.6M, based on as-reported figures from SEC (XBRL) filings.
What is AN2 Therapeutics, Inc. Common Stock's Net Income (TTM)?
AN2 Therapeutics, Inc. Common Stock's Net Income (TTM) is -$36.3M, based on as-reported figures from SEC (XBRL) filings.
What is AN2 Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
AN2 Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.96, based on as-reported figures from SEC (XBRL) filings.
What is AN2 Therapeutics, Inc. Common Stock's Net Debt?
AN2 Therapeutics, Inc. Common Stock's Net Debt is -$44.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ANTXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Interest income
Other expense——
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic
Net loss per share attributable to common stockholders, diluted